0001213900-26-044125
SEC filingMainz Biomed entered into an asset purchase agreement to sell its Next Gen colorectal cancer IP for $1.25 million and believes it now complies with Nasdaq's minimum stockholders' equity requirement after $6 million in equity investments.
Mainz Biomed B.V. has strategically shifted focus from colorectal cancer products to pancreatic cancer screening and post-quantum cybersecurity by entering a material asset purchase agreement on April 9, 2026, for its Next Gen colorectal cancer IP. The $1.25 million cash sale to an Italian third-party, set to close by April 23, 2026 (potentially extendable), is subject to standard conditions including third-party consents, material shipments, and patent extensions, with typical representations and indemnities. This follows the March 28, 2026, ColoAlert IP sale and February 2026 wind-down of related operations and staff, enabling cost reductions. Proceeds will address liabilities and corporate needs without disrupting core pancreatic cancer development. Separately, $6 million from preferred share tranches ($3 million closed February 13, 2026; $3 million prepaid March 2026) resolved Nasdaq non-compliance, lifting stockholders’ equity from $641,600 (December 31, 2025, below $2.5 million Rule 5550(b)(1)) to above the threshold. Investors should monitor closing risks and equity position verification.